Scribe Therapeutics reported second-quarter 2026 financial results and pipeline progress.
The company initiated a first-in-human phase 1 clinical trial of STX-1150 in Australia in mid-2026, according to the company, and presented late-breaking non-human primate data at the European Atherosclerosis Society showing up to 90% PCSK9 silencing and LDL-C reductions up to 68%, with a 0.75 mg/kg dose producing greater than 50% LDL-C reductions sustained for two years and no adverse clinical observations reported.
Scribe received approximately $25.7 million in combined non-dilutive funding from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400 toward potential clinical entry as early as 2027.
The company completed an upsized initial public offering and a concurrent private placement to Sanofi, generating about $155.5 million in aggregate gross proceeds and beginning Nasdaq trading under the ticker SCTX on 24 July 2026.
As of 30 June 2026, cash, cash equivalents and marketable securities totaled $43.0 million, and the company states that approximately $140.6 million of net proceeds from the July transactions provides funding into the first half of 2029.
For the quarter, the company reported collaboration revenue of $1.9 million, research and development expenses of $8.8 million, general and administrative expenses of $2.5 million, and a net loss of $6.5 million, or $2.62 per share.
